flow cytometry

This discussion with Dr. Johan Skog covers a lot of ground while staying super approachable. 

The Founder and Chief Scientific Officer of Exosome Diagnostics, starts by sharing basics about exosomes and tells us about how he’s translated his curiosity for the vesicles from tumor stem cells into his current role where he’s helped develop the world’s first exosome-based cancer diagnostic test. The conversation delves into the variations in exosomes populations, the value of using multiple biomarkers in diagnostics, the role that isolation and purification play in using exosomes for diagnostics, and why some cancers are better left untreated. 

Join us for this fascinating conversation with an innovator, that just happens to have one of the most soothing voices around. 

Subscribe to get future episodes as they drop and if you like what you’re hearing we hope you’ll share a review or recommend the series to a colleague. 

Visit https://thermofisher.com/molbioschool to access the Invitrogen School of Molecular Biology, which is packed with really helpful molecular biology resources and educational content. 

Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode. 
Watch now at thermofisher.com/podcast-video

Subscribe to get future episodes as they drop and if you like what you’re hearing we hope you’ll share a review or recommend the series to a colleague. 

Download Transcripts: 

Speaking of Mol Bio Podcast | Thermo Fisher Scientific - US

Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. 

(00:32):

Before we get into the test itself, Dr. Mills, I'd love for you to tell our audience just a little bit about yourself, your background, your role here at Mayo clinic.

(01:41):

Can you just give our audience a brief overview of the assay?

(05:20):

I really appreciate how the lab has looked at other approaches and decided that this is the best one. Is that an accurate kind of summary.

(06:16):

They'll get the result that they need with just one test, right?

(07:03):

So can you start with helping our physicians understand which patients should get this testing?

(09:05):

You said these immune mediated neuropathies, this test is going to be important for all of those to help, to identify the distinct phenotype of neurofascin155, right, Dr. Mills?

(09:43):

I know you mentioned that these are rare disorders, but how common is the neurofascin antibody in that phenotype?

(11:27):

Dr. Mills, are there any other alternative options regarding this kind of testing?

(13:30):

How is the positive or negative result going to drive the physician in a certain direction regarding prognosis or treatment? Can you share some of that?

(14:48):

Do you think there are any prerequisites that physicians should be testing for these particular things before they would order our neurofascin test or does the neurofascin come pretty early on in the differential?

(15:36):

Can you elaborate a little more on the next steps? What does a more aggressive treatment plan? What does that mean?

(16:09):

We've talked about a lot of the important items, the assay and how it's designed, how this is going to help patient care and how it's unique, but what's your key takeaway here? What are you most excited about?